These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25256057)

  • 1. Living-donor kidney transplantation for atypical haemolytic uremic syndrome with pre-emptive eculizumab use.
    Parikova A; Fronek JP; Viklicky O
    Transpl Int; 2015 Mar; 28(3):366-9. PubMed ID: 25256057
    [No Abstract]   [Full Text] [Related]  

  • 2. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.
    Ranch D; Crowther B; Arar M; Assanasen C
    Pediatr Transplant; 2014 Sep; 18(6):E185-9. PubMed ID: 24931815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.
    Legendre CM; Campistol JM; Feldkamp T; Remuzzi G; Kincaid JF; Lommelé Å; Wang J; Weekers LE; Sheerin NS
    Transpl Int; 2017 Dec; 30(12):1275-1283. PubMed ID: 28801959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
    Zuber J; Frimat M; Caillard S; Kamar N; Gatault P; Petitprez F; Couzi L; Jourde-Chiche N; Chatelet V; Gaisne R; Bertrand D; Bamoulid J; Louis M; Sberro Soussan R; Navarro D; Westeel PF; Frimat L; Colosio C; Thierry A; Rivalan J; Albano L; Arzouk N; Cornec-Le Gall E; Claisse G; Elias M; El Karoui K; Chauvet S; Coindre JP; Rerolle JP; Tricot L; Sayegh J; Garrouste C; Charasse C; Delmas Y; Massy Z; Hourmant M; Servais A; Loirat C; Fakhouri F; Pouteil-Noble C; Peraldi MN; Legendre C; Rondeau E; Le Quintrec M; Frémeaux-Bacchi V
    J Am Soc Nephrol; 2019 Dec; 30(12):2449-2463. PubMed ID: 31575699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Renal Transplantation in a Patient with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab in China.
    Sun ZJ; Du X; Su LL; Zhang XD; Wang Y; Ren L; Wang W
    Chin Med J (Engl); 2016 Jun; 129(11):1379-81. PubMed ID: 27231180
    [No Abstract]   [Full Text] [Related]  

  • 7. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
    Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
    Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.
    van den Brand JA; Verhave JC; Adang EM; Wetzels JF
    Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i115-i122. PubMed ID: 28391343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome.
    Kasapoğlu U; Ruhi Ç; Tuğcu M; Boynueğri B; Titiz İ; Hançer VS; Apaydın S
    Ann Transplant; 2015 Dec; 20():714-9. PubMed ID: 26621268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation.
    Java A
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):128-137. PubMed ID: 32553245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab for aHUS post-transplantation: when and how to stop a good thing.
    Masengu A; Courtney A
    Transpl Int; 2015 Aug; 28(8):1000-1. PubMed ID: 25790226
    [No Abstract]   [Full Text] [Related]  

  • 13. Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab.
    Choo SZ; Brown F
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():4-6. PubMed ID: 28176471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical hemolytic uremic syndrome recurrence after kidney transplantation.
    Matar D; Naqvi F; Racusen LC; Carter-Monroe N; Montgomery RA; Alachkar N
    Transplantation; 2014 Dec; 98(11):1205-12. PubMed ID: 24933457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful kidney transplant with eculizumab, thymoglobulin and belatacept therapy in a highly-sensitised patient with atypical haemolytic uraemic syndrome due to factor H mutation.
    Nieto-Ríos JF; Zuluaga-Quintero M; Bello-Márquez DC; Aristizabal-Alzate A; Ocampo-Kohn C; Serna-Higuita LM; Arias L; Zuluaga-Valencia G
    Nefrologia (Engl Ed); 2018; 38(4):433-437. PubMed ID: 29778558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome.
    Verhave JC; Westra D; van Hamersvelt HW; van Helden M; van de Kar NC; Wetzels JF
    Neth J Med; 2013 Sep; 71(7):342-7. PubMed ID: 24038559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft.
    Alachkar N; Bagnasco SM; Montgomery RA
    Transpl Int; 2012 Aug; 25(8):e93-5. PubMed ID: 22591029
    [No Abstract]   [Full Text] [Related]  

  • 20. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.
    Dedhia P; Govil A; Mogilishetty G; Alloway RR; Woodle ES; Abu Jawdeh BG
    Transplant Proc; 2017; 49(1):188-192. PubMed ID: 28104134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.